Cargando…
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer
Blood-based biomarkers including systemic inflammation (SI) indicators or circulating factors (cytokines, chemokines, or growth factors) are associated with a poor prognosis for lung cancer patients. Collectively these biomarkers can predict the immune state of a patient. We wanted to define and com...
Autores principales: | Rice, Shawn J., Belani, Chandra P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638918/ https://www.ncbi.nlm.nih.gov/pubmed/34855926 http://dx.doi.org/10.1371/journal.pone.0260988 |
Ejemplares similares
-
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015) -
Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015) -
EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer
por: Rice, Shawn J., et al.
Publicado: (2019) -
Expression of PD-1 on CD4(+) T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer
por: Zheng, Hong, et al.
Publicado: (2016) -
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
por: Jia, Qingzhu, et al.
Publicado: (2018)